DUBLIN--(BUSINESS WIRE)--The "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
- The report provides a snapshot of the pipeline development for Paroxysmal Nocturnal Hemoglobinuria
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Paroxysmal Nocturnal Hemoglobinuria
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Paroxysmal Nocturnal Hemoglobinuria
- The report also covers the dormant and discontinued pipeline projects related to Paroxysmal Nocturnal Hemoglobinuria
- Achillion Pharmaceuticals Inc.
- Akari Therapeutics PLC
- Alexion Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- Apellis Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
- ISU ABXIS Co Ltd.
- Novartis AG
- NovelMed Therapeutics Inc.
- Omeros Corp.
- R Pharmaceuticals Inc.
Key Topics Covered
1. Report Introduction
2. Paroxysmal Nocturnal Hemoglobinuria Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pdzgj8/paroxysmal?w=4